Free tool
FAERS Monitor: Zokinvy
Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 213969 or its brand name (Zokinvy, Lonafarnib). Reports on generic versions are filed under their own applications.
Reports
78
Serious
42
54% of reports
Hospitalization
25
Death reported
12
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product dose omission issue23
- diarrhoea16
- vomiting12
- death4
- headache4
- abdominal pain upper3
- asthenia3
- cardiac operation3
- fatigue3
- malaise3
- nausea3
- product supply issue3
- pyrexia3
- abdominal discomfort2
- anaemia2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 5 |
| 2009 | 1 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 2 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 21 |
| 2022 | 15 |
| 2023 | 9 |
| 2024 | 7 |
| 2025 | 2 |
| 2026 | 2 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,081 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product supply issueSignal | 3 | 113.4 | 37.4 | 231 |
| cardiac operationSignal | 3 | 94.1 | 31.0 | 191 |
| product dose omission issueSignal | 23 | 21.1 | 15.0 | 426 |
| vomitingSignal | 12 | 6.9 | 4.1 | 56 |
| diarrhoeaSignal | 16 | 6.7 | 4.3 | 74 |
| abdominal pain upper | 3 | 3.9 | 1.3 | 4 |
| abdominal discomfort | 2 | 3.2 | 0.8 | 1 |
| anaemia | 2 | 2.8 | 0.7 | 1 |
| pyrexia | 3 | 2.3 | 0.8 | 1 |
| asthenia | 3 | 2.2 | 0.7 | 1 |
| malaise | 3 | 1.8 | 0.6 | 0 |
| headache | 4 | 1.7 | 0.7 | 1 |
| death | 4 | 1.3 | 0.5 | 0 |
| fatigue | 3 | 1.0 | 0.3 | 0 |
| nausea | 3 | 1.0 | 0.3 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.